Riskpilot← Back to searchSign inGet full accessMETRONOR MEDTECH AS
ASActiveOrg 928672085Gamle Borgenvei 3, 1383 AskerManufacture of instruments and appliances for measuring, testing and navigation · NACE 2651Est. 20220 employees
Revenue 2024
NOK 0
EBITDA margin
—
-63% vs 2023
Equity ratio
79.7%
Financial strength
Net profit 2024
NOK -924K
-69% vs 2023
| Revenue | NOK 0 | — |
| EBITDA | NOK -1,1M | -63% |
| Net profit | NOK -924K | -69% |
| Total assets | NOK 10,2M | +5% |
| Equity | NOK 8,1M | +0% |
| Employees | 0 | — |
Legal name
METRONOR MEDTECH AS
Org number
928672085
Legal form
Aksjeselskap
NACE code
2651 · Manufacture of instruments and appliances for measuring, testing and navigation
Founded
5. februar 2022
Share capital
NOK 100 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
To styremedlemmer i fellesskap.
Company purpose
Utvikling, produksjon og markedsføring av systemer for navigasjon, posisjonering og geometrimåling for medisinsk forskning og virksomhet, herunder annen forenlig virksomhet samt eksport og import av sådan teknologi. Det skal være anledning til å delta i andre selskaper.
Address
Gamle Borgenvei 3, 1383 Asker
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | 0 | 0 | 0 |
| Staff expenses | −0 | −0 | −108 |
| EBITDA | −511 | −698 | −1 137 |
| Depreciation & amort. | −0 | −0 | −0 |
| EBIT | −511 | −698 | −1 137 |
| Net financials | 0 | −1 | −44 |
| Profit before tax | −511 | −699 | −1 181 |
| Tax | −112 | −152 | −258 |
| Net profit | −400 | −547 | −924 |
| Item | 2022 | 2023 | 2024 |
|---|---|---|---|
| Total assets | 8 896 | 9 697 | 10 180 |
| Equity | 8 132 | 8 122 | 8 112 |
| Long-term debt | 0 | 0 | 0 |
| Short-term debt | 764 | 1 575 | 2 068 |
| Total debt | 764 | 1 575 | 2 068 |
EBITDA margin
-113706800.0%
This company
15.8%
Market median
-719663391% vs market
20222024
Equity ratio
79.7%
This company
38.2%
Market median
+109% vs market
20222024
Return on equity
-11.4%
This company
18.4%
Market median
-162% vs market
20222024
Net profit margin
-92368000.0%
This company
8.1%
Market median
-1140345779% vs market
20222024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20222024
Debt / equity
0.25×
This company
0.62×
Market median
+60% vs market
20222024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2021-07-26 – 2022-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
ØR Chief Executive Officer | Chief Executive Officer | 2022 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2022 | — | — | |
| Chairman | 2022 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Metronor Holding As | Company | 100.0% | 100.0% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Metronor Holding As
METRONOR MEDTECH AS Board members of METRONOR MEDTECH AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Øyvind Røtvold | Chief Executive Officer | 0 companies |
| Lars Øberg | Board of Directors | 0 companies |
| Arvid Strand | Board of Directors | 0 companies |
| Svein Otto Garberg | Board of Directors | 0 companies |
| Carl Lennart Jakobsson | Board of Directors | 0 companies |
| Arnstein Nordbotten | Chairman | 0 companies |